Benzo thiadiazine matrix metalloproteinase inhibitors
US6656932B2 · kind B2 · utility
38Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2002 |
| Grant date | Dec 2, 2003 |
| Priority date | — |
| Expiry date | Feb 13, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Selective MMP-13 inhibitors are benzo thiadiazines of the Formula or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or alkyl; R1 and R3 include hydrogen, alkyl, and aryl, with the proviso that R3 is not (CH2)m biphenyl or (CH2)m substituted biphenyl; X is O or NH, n is 0, 1, or 2. The compounds of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating diseases mediated by an MMP-13 enzyme, including diseases selected from osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.